BDTX (Black Diamond Therapeutics, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by BDTX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-29 | Shannon Campbell | Director | A | — | — |
| 2026-06-29 | Garry E Menzel | Director | A | — | — |
| 2026-06-29 | Kapil Dhingra | Director | A | — | — |
| 2026-06-29 | Ali Behbahani | Director | A | — | — |
| 2026-06-29 | Prakash Raman | Director | A | — | — |
| 2026-06-29 | Samarth Kulkarni | Director | A | — | — |
| 2026-06-22 | Prakash Raman | Director | A | — | — |
| 2026-06-22 | Ali Behbahani | Director | A | — | — |
| 2026-03-20 | Prakash Raman | Director | A | — | — |
| 2026-03-20 | Ali Behbahani | Director | A | — | — |
| 2026-01-23 | Mark A. Velleca | PRESIDENT & CEO | A | — | — |
| 2026-01-23 | Elizabeth Buck | CHIEF SCIENTIFIC OFFICER | A | — | — |
| 2026-01-23 | Erika Jones | SEE REMARKS | A | — | — |
| 2026-01-23 | Sergey Yurasov | CHIEF MEDICAL OFFICER | A | — | — |
| 2026-01-23 | Brent Hatzis-Schoch | SEE REMARKS | A | — | — |
| 2025-12-15 | Prakash Raman | Director | A | — | — |
| 2025-12-15 | Ali Behbahani | Director | A | — | — |
| 2025-09-22 | Prakash Raman | Director | A | — | — |
| 2025-09-22 | Ali Behbahani | Director | A | — | — |
| 2025-06-20 | Ali Behbahani | Director | A | — | — |
| 2025-06-20 | Prakash Raman | Director | A | — | — |
| 2025-06-12 | Ali Behbahani | Director | A | — | — |
| 2025-06-12 | Garry E Menzel | Director | A | — | — |
| 2025-06-12 | Shannon Campbell | Director | A | — | — |
| 2025-06-12 | Kapil Dhingra | Director | A | — | — |
| 2025-06-12 | Prakash Raman | Director | A | — | — |
| 2025-06-12 | Samarth Kulkarni | Director | A | — | — |
| 2025-03-21 | Prakash Raman | Director | A | — | — |
| 2025-03-21 | Ali Behbahani | Director | A | — | — |
| 2025-03-20 | BB BIOTECH AG | 10%+ Owner | Sell | — | — |
| 2025-01-31 | Mark A. Velleca | PRESIDENT & CEO | A | — | — |
| 2025-01-31 | Sergey Yurasov | CHIEF MEDICAL OFFICER | A | — | — |
| 2025-01-31 | Brent Hatzis-Schoch | SEE REMARKS | A | — | — |
| 2025-01-31 | Elizabeth Buck | CHIEF SCIENTIFIC OFFICER | A | — | — |
| 2025-01-31 | Erika Jones | SEE REMARKS | A | — | — |
| 2024-12-16 | Prakash Raman | Director | A | — | — |
| 2024-12-16 | Shannon Campbell | Director | A | — | — |
| 2024-12-16 | Ali Behbahani | Director | A | — | — |
| 2024-09-20 | Prakash Raman | Director | A | — | — |
| 2024-09-20 | Shannon Campbell | Director | A | — | — |
| 2024-09-20 | Ali Behbahani | Director | A | — | — |
| 2024-08-30 | Versant Vantage I, L.P. | 10%+ Owner | Sell | — | — |
| 2024-06-21 | Shannon Campbell | Director | A | — | — |
| 2024-06-21 | Ali Behbahani | Director | A | — | — |
| 2024-06-21 | Prakash Raman | Director | A | — | — |
| 2024-06-06 | Ali Behbahani | Director | A | — | — |
| 2024-06-06 | Kapil Dhingra | Director | A | — | — |
| 2024-06-06 | Prakash Raman | Director | A | — | — |
| 2024-06-06 | Samarth Kulkarni | Director | A | — | — |
| 2024-06-06 | Shannon Campbell | Director | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 8,517,839 | — |
| — | 10%+ Owner | 7,517,839 | — |
| — | 10%+ Owner | 6,365,666 | — |
| — | 10%+ Owner | 5,225,482 | — |
| — | Director | 4,551,286 | — |
| — | 10%+ Owner | 4,343,210 | — |
| — | 10%+ Owner | 4,107,283 | — |
| — | Director | 3,213,828 | — |
| — | 10%+ Owner | 778,790 | — |
| — | SEE REMARKS | 694,513 | — |
| — | 10%+ Owner | 568,185 | — |
| — | Director | 311,926 | — |
| — | CHIEF SCIENTIFIC OFFICER | 170,192 | — |
| — | PRESIDENT & CEO | 121,522 | — |
| — | SEE REMARKS | 89,026 | — |
| — | SEE REMARKS | 85,150 | — |
| — | SEE REMARKS | 83,400 | — |
| — | CHIEF MEDICAL OFFICER | 75,000 | — |
| — | Director | 51,825 | — |
| — | Director | 45,039 | — |
| — | Director | 42,854 | — |
| — | Director | 38,054 | — |
| — | Director | 21,851 | — |
| — | Chief Medical Officer | 10,000 | — |
| — | Director | 8,865 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the BDTX quote page; the site-wide leaderboard is on the insider transactions hub.